Moderna (NASDAQ:MRNA) Stock Price Expected to Rise, Leerink Partners Analyst Says

Moderna (NASDAQ:MRNA) had its price target lifted by stock analysts at Leerink Partners from $15.00 to $18.00 in a research note issued on Friday,Benzinga reports. The firm currently has an “underperform” rating on the stock. Leerink Partners’ target price indicates a potential downside of 24.11% from the stock’s current price.

Several other equities research analysts also recently issued reports on MRNA. Berenberg Bank set a $28.00 price objective on Moderna in a report on Monday, November 17th. Barclays cut their price target on shares of Moderna from $31.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Friday, November 7th. Royal Bank Of Canada reduced their price target on shares of Moderna from $28.00 to $25.00 and set a “sector perform” rating on the stock in a research report on Friday. Needham & Company LLC restated a “hold” rating on shares of Moderna in a report on Monday, October 20th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Moderna in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus target price of $29.46.

Moderna Stock Performance

Shares of MRNA stock opened at $23.72 on Friday. The firm has a market cap of $9.27 billion, a P/E ratio of -2.94 and a beta of 2.02. The firm’s 50 day moving average price is $25.87 and its 200-day moving average price is $26.96. Moderna has a one year low of $22.28 and a one year high of $48.92.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, November 6th. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($2.15) by $1.64. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $893.29 million. During the same quarter last year, the firm earned $0.03 EPS. The firm’s revenue for the quarter was down 45.4% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. As a group, research analysts predict that Moderna will post -9.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Moderna

A number of hedge funds and other institutional investors have recently modified their holdings of MRNA. S Bank Fund Management Ltd purchased a new stake in shares of Moderna during the 1st quarter worth $25,000. Rothschild Investment LLC raised its stake in Moderna by 94.1% in the second quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock valued at $25,000 after buying an additional 446 shares in the last quarter. TD Private Client Wealth LLC lifted its holdings in Moderna by 348.8% during the 2nd quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock worth $26,000 after buying an additional 743 shares during the last quarter. Atlantic Union Bankshares Corp acquired a new position in shares of Moderna during the 2nd quarter worth about $26,000. Finally, SVB Wealth LLC acquired a new position in shares of Moderna during the 1st quarter worth about $28,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.